Prince Pharmaceutical Co (ROCO:6935) Beneish M-Score: -2.11 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6935 Prince Pharmaceutical Co Ltd ROCO:6935
60 GF Score
Price NT$30.25
GF Value NT$42.11
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Prince Pharmaceutical Co Beneish M-Score?

Prince Pharmaceutical Co ROCO:6935 +0.33% 60 Beneish M-Score is -2.11 as of Jul. 14, 2026. GuruFocus rates ROCO:6935 with a GF Score™ of 60/100 and a GF Value™ of NT$42.11 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 911 Drug Manufacturers companies, Prince Pharmaceutical Co ranks worse than 74.2% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.11 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Prince Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

ROCO:6935' s Beneish M-Score Range Over the Past 10 Years
Min: -2.52   Med: -2.31   Max: -2.11
Current: -2.11

During the past 7 years, the highest Beneish M-Score of Prince Pharmaceutical Co was -2.11. The lowest was -2.52. And the median was -2.31.


Prince Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Prince Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prince Pharmaceutical Co Beneish M-Score Chart

Prince Pharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -2.31 -2.34 -2.15 -2.52 -2.11

Prince Pharmaceutical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.15 0.00 -2.52 0.00 -2.11

ROCO:6935 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Prince Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prince Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prince Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Prince Pharmaceutical Co's Beneish M-Score falls into.


ROCO:6935
60GF Score
Prince Pharmaceutical Co Ltd ROCO:6935
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prince Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Prince Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1042+0.528 * 0.5109+0.404 * 0.9302+0.892 * 1.5307+0.115 * 0.9734
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6673+4.679 * 0.004166-0.327 * 0.9524
=-2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$197 Mil.
Revenue was NT$1,056 Mil.
Gross Profit was NT$223 Mil.
Total Current Assets was NT$561 Mil.
Total Assets was NT$1,503 Mil.
Property, Plant and Equipment(Net PPE) was NT$933 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$62 Mil.
Selling, General, & Admin. Expense(SGA) was NT$77 Mil.
Total Current Liabilities was NT$310 Mil.
Long-Term Debt & Capital Lease Obligation was NT$354 Mil.
Net Income was NT$96 Mil.
Gross Profit was NT$0 Mil.
Cash Flow from Operations was NT$90 Mil.
Total Receivables was NT$117 Mil.
Revenue was NT$690 Mil.
Gross Profit was NT$74 Mil.
Total Current Assets was NT$365 Mil.
Total Assets was NT$1,348 Mil.
Property, Plant and Equipment(Net PPE) was NT$974 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$62 Mil.
Selling, General, & Admin. Expense(SGA) was NT$75 Mil.
Total Current Liabilities was NT$235 Mil.
Long-Term Debt & Capital Lease Obligation was NT$390 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(197.125 / 1056.201) / (116.632 / 690.025)
=0.186636 / 0.169026
=1.1042

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(74.278 / 690.025) / (222.55 / 1056.201)
=0.107645 / 0.210708
=0.5109

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (560.889 + 932.723) / 1503.486) / (1 - (365.128 + 973.6) / 1348.247)
=0.006567 / 0.00706
=0.9302

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1056.201 / 690.025
=1.5307

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(62.493 / (62.493 + 973.6)) / (61.614 / (61.614 + 932.723))
=0.060316 / 0.061965
=0.9734

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(77.036 / 1056.201) / (75.426 / 690.025)
=0.072937 / 0.109309
=0.6673

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((353.961 + 309.905) / 1503.486) / ((390.379 + 234.713) / 1348.247)
=0.441551 / 0.463633
=0.9524

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(96.321 - 0 - 90.057) / 1503.486
=0.004166

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Prince Pharmaceutical Co has a M-score of -2.11 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.11 mean?
Prince Pharmaceutical Co (ROCO:6935) has a Beneish M-Score of -2.11 as of Jul. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Prince Pharmaceutical Co and its competitors. According to the industry distribution chart, Prince Pharmaceutical Co ranks #676 out of 911 companies in the Drug Manufacturers industry, placing it in the top 74.2%.
Is Prince Pharmaceutical Co's Beneish M-Score too high?
Prince Pharmaceutical Co's current Beneish M-Score is -2.11. Based on the distribution chart, Prince Pharmaceutical Co ranks #676 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Prince Pharmaceutical Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prince Pharmaceutical Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Prince Pharmaceutical Co ranks #676 out of 911 companies for Beneish M-Score. This places Prince Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Prince Pharmaceutical Co and its competitors. Prince Pharmaceutical Co's current Beneish M-Score is -2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prince Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Prince Pharmaceutical Co (ROCO:6935) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$42.11, compared to a current price of NT$30.25 — trading 28.2% below its estimated fair value. The current Beneish M-Score is -2.11. Prince Pharmaceutical Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Prince Pharmaceutical Co (ROCO:6935), the current Beneish M-Score is -2.11 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prince Pharmaceutical Co (ROCO:6935) Overvalued in 2026?

Based on GuruFocus' analysis, Prince Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$30.25 is trading 28.2% below its estimated GF Value™ of NT$42.11. GuruFocus considers Prince Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for ROCO:6935:

  • Beneish M-Score: -2.11
  • GF Value™: NT$42.11 vs. price of NT$30.25 (28.2% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6935 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Prince Pharmaceutical Co Business Description

Address Number 168, Keyunnan Road, Huwei Town, Yunlin, TWN, 632
Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe and other regions.
60GF Score

Get the complete analysis for ROCO:6935

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.25
Price
NT$42.11
GF Value